Insights into future therapeutics for atopic dermatitis

References

• Hong J, Buddenkotte J, Berger TG, et al. Management of itch in atopic dermatitis. Semin Cutan Med Surg. 2011;30(2):71–86.
   PubMed Web of Science ®Google Scholar
• Blume-Peytavi U, Metz M. Atopic dermatitis in children: management of pruritus. J Eur Acad Dermatol Venereol. 2012;26 Suppl 6:2–8.
   PubMed Web of Science ®Google Scholar
• Margolis DJ, Abuabara K, Hoffstad OJ, et al. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 2015;151(6):594.
   PubMed Web of Science ®Google Scholar
• Ibler KS, Jemec GB. Novel investigational therapies for atopic dermatitis. Expert Opin Investig Drugs. 2015;24(1):61–68.
   PubMed Web of Science ®Google Scholar
• Wolter S, Price HN. Atopic dermatitis. Pediatr Clin North Am. 2014;61(2):241–260.
   PubMed Web of Science ®Google Scholar
• Walling HW, Swick BL. Update on the management of chronic eczema: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol. 2010;3:99–117.
   PubMedGoogle Scholar
• Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol. 1995;105(1):S84–S88.
   Web of Science ®Google Scholar
• Jarnagin K, Chanda S, Coronado D, et al. Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J Drugs Dermatol. 2016;15(4):390–396. [cited 2016 Dec 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27050693.
   PubMed Web of Science ®Google Scholar
• Stein Gold LF, Spelman L, Spellman MC, et al., A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol. 2015;14(12):1394–1399. [cited 2017 Feb 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26659931.
   PubMed Web of Science ®Google Scholar
• Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494–503.e4.
   PubMed Web of Science ®Google Scholar
• Anacor pharmaceuticals announces positive preliminary results from phase 2a trial of AN2728 and AN2898 in atopic dermatitis. BusinessWire. 2015 Available from: https://www.enhancedonlinenews.com/news/eon/20150713005450/en
   Google Scholar
• Nemoto O, Hayashi N, Kitahara Y, et al. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: results from a randomized, vehicle-controlled exploratory trial. J Dermatol. 2016;43(8):881–887.
   PubMed Web of Science ®Google Scholar
• Furue M, Kitahara Y, Akama H, et al. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol. 2014;41(7):577–585.
   PubMed Web of Science ®Google Scholar
• Ohba F, Matsuki S, Imayama S, et al. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: an investigator-blinded, vehicle-controlled study. J Dermatolog Treat. 2016;27(5):467–472.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Ellis CN, Frieden IJ, et al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2016;75(2):297–305.
   PubMed Web of Science ®Google Scholar
• Wang D, Beck LA. Immunologic targets in atopic dermatitis and emerging therapies: an update. Am J Clin Dermatol. 2016;17(5):425–443.
   PubMed Web of Science ®Google Scholar
• Slominski A, Pisarchik A, Zbytek B, et al. Functional activity of serotoninergic and melatoninergic systems expressed in the skin. J Cell Physiol. 2003;196(1):144–153.
   PubMed Web of Science ®Google Scholar
• Palmqvist N, Siller M, Klint C, et al. A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030. J Inflamm. 2016;13(1):20.
   Google Scholar
• Peltonen J, Pylkkänen L, Jansén C, et al. Three randomised phase I/IIa trials of 5% cis-urocanic acid emulsion cream in healthy adult subjects and in patients with atopic dermatitis. Acta Derm Venereol. 2014;94(4):415–420.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Poulin Y, Zhou Y, et al. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012;166(4):853–860.
   PubMed Web of Science ®Google Scholar
• Ouedraogo ZG, Fouache A, Trousson A, et al. Role of the liver X receptors in skin physiology: putative pharmacological targets in human diseases. Chem Phys Lipids. 2017 Mar;207:59–68.
   PubMed Web of Science ®Google Scholar
• Battersby AJ, Khara J, Wright VJ, et al. Antimicrobial proteins and peptides in early life: ontogeny and translational opportunities. Front Immunol. 2016;7:309.
   PubMed Web of Science ®Google Scholar
• Pintér E, Pozsgai G, Hajna Z, et al. Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions. Br J Clin Pharmacol. 2014;77(1):5–20.
   PubMed Web of Science ®Google Scholar
• Machelska H, Pflüger M, Weber W, et al. Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J Pharmacol Exp Ther. 1999;290(1):354–361. [Accessed 2017 Feb 16]. http://www.ncbi.nlm.nih.gov/pubmed/10381799.
   PubMed Web of Science ®Google Scholar
• Werfel T. Overview of ZPL-3893787 (ZPL-389) clinical trial for atopic dermatitis. Eur Med J. 2016. [cited 2017 Feb 16]. Available from: http://emjreviews.com/videos/overview-of-zpl-3893787-zpl-389-clinical-trial-for-atopic-dermatitis/.
   Google Scholar
• Millan MJ, Członkowski A, Morris B, et al. Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. Pain. 1988;35(3):299–312. [cited 2017 Feb 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2906425.
   PubMed Web of Science ®Google Scholar
• Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol. 2007;127(9):2228–2235.
   PubMed Web of Science ®Google Scholar
• Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95(5):542–548.
   PubMed Web of Science ®Google Scholar
• Lim K-M, Park Y-H. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012;35(3):393–396.
   PubMed Web of Science ®Google Scholar
• Yun J-W, Seo JA, Jeong YS, et al. TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery. J Dermatol Sci. 2010;62(1):8–15.
   PubMed Web of Science ®Google Scholar
• Dastidar SG, Rajagopal D, Ray A, Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs. 2007;8(5):364–372. [cited 2017 Feb 13]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17520865.
   PubMed Web of Science ®Google Scholar
• Wittmann M, Helliwell PS. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol Ther (Heidelb). 2013;3(1):1–15.
   PubMedGoogle Scholar
• Mease PJ. Apremilast: a phosphodiesterase 4 inhibitor for the treatment of psoriatic arthritis. Rheumatol Ther. 2014;1(1):1–20.
   PubMedGoogle Scholar
• Samrao A, Berry TM, Goreshi R, et al. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148(8):890–897.
   PubMedGoogle Scholar
• Volf EM, Au S-C, Dumont N, et al., A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol. 2012;11(3):341–346. [cited 2017 Feb 13]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22395585.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Gadina M. Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol. 2014;23(1):7–11.
   PubMed Web of Science ®Google Scholar
• Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015;73(3):395–399.
   PubMed Web of Science ®Google Scholar
• Bowton DL, Dmitrienko AA, Israel E, et al., Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma. J Asthma. 2005;42(1):65–71. [cited 2017 Feb 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15801331.
   PubMed Web of Science ®Google Scholar
• Patel NU, D’Ambra V, Feldman SR. Increasing adherence with topical agents for atopic dermatitis. Am J Clin Dermatol. 2017 Feb;18:323–332.
   PubMed Web of Science ®Google Scholar